Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Current Evidence and Future Perspective in the Exploration of Sleep-Related Eating Disorder—From Pathogenic Hypotheses to Treatment Approaches

Version 1 : Received: 14 October 2023 / Approved: 16 October 2023 / Online: 17 October 2023 (08:11:30 CEST)

How to cite: Vasiliu, O. Current Evidence and Future Perspective in the Exploration of Sleep-Related Eating Disorder—From Pathogenic Hypotheses to Treatment Approaches. Preprints 2023, 2023100976. https://doi.org/10.20944/preprints202310.0976.v1 Vasiliu, O. Current Evidence and Future Perspective in the Exploration of Sleep-Related Eating Disorder—From Pathogenic Hypotheses to Treatment Approaches. Preprints 2023, 2023100976. https://doi.org/10.20944/preprints202310.0976.v1

Abstract

Sleep-related eating disorder (SRED) is a non-REM parasomnia with potentially significant negative effects on general health (dangerous activities during night eating episodes, obesity, or metabolic syndrome, for example). Although the history of SRED encompasses more than six decades, public awareness and even the awareness of the mental health specialists of this disorder is very limited, a phenomenon that hinders the development of research in this field. Therefore, an updated review, based on a narrative methodology, explored the available evidence for SRED found in four electronic databases (PubMed, Cochrane Collaboration, Google Scholar, and Clarivate/Web of Science). A number of 94 primary and secondary reports were retrieved, investigating aspects regarding the risk factors, epidemiology, clinical data and differential diagnosis, epidemiology, structured evaluation, and treatment of SRED. Based on the results of these reports, Z-drugs, but also certain benzodiazepines, antidepressants, antipsychotics, and psychostimulants may trigger the onset of SRED. Psychiatric and neurologic disorders have also been associated with SRED, either as risk factors or comorbid conditions. Cerebral glucose metabolism dysfunctions, neurotransmitter dysfunctions, and genetic factors have been invoked as pathogenetic contributors. Structured assessment of SRED is possible, but there is a dearth of instruments dedicated to this purpose. Data on the prevalence and treatment of SRED exist, but good-quality epidemiological studies and clinical trials are still missing. In conclusion, future research is expected to address the shortcomings of SRED exploration by creating the conditions for better quality and larger group clinical research. The need for such investigation is granted by the importance of this pathology and its negative functional consequences.

Keywords

sleep-related eating disorder; night eating syndrome; parasomnia; disorders of arousal; topiramate; clonazepam; pramipexole; zolpidem

Subject

Medicine and Pharmacology, Psychiatry and Mental Health

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.